![]() |
市场调查报告书
商品编码
1289639
三维蛋白质结构分析市场 - 2017-2027年全球行业规模、份额、趋势、机会和预测,按组件、技术、终端用户、公司和地区划分3D Protein Structure Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technique, By End User, By company and By Region |
全球三维蛋白质结构分析市场预计将在2023-2027年预测期内出现令人印象深刻的增长。主要因素包括越来越关注X射线晶体学工作流程的自动化和小型化,采用先进技术,以及研发活动的增加,这些都促进了市场的增长。蛋白质结构基本上是一个氨基酸中原子的三维排列。蛋白质的三维结构可以通过大型蛋白质的结晶,然后通过X射线衍射来确定。蛋白质的功能与该蛋白质的结构直接相关。支持市场增长的其他因素有:对蛋白质治疗的需求上升,慢性病、传染病和蛋白质缺乏症的发病率上升,研究实验室的数量增加,对个性化药物的高需求,以及政府拨款的增加。另外,用于药物发现和开发的研究与开发(R&D)支出的上升也促进了市场的增长。
X射线晶体学是一种技术,通过X射线衍射可以获得蛋白质的三维结构,这有助于了解蛋白质的功能。对现有晶体学的自动化和小型化的日益重视,增强了市场的增长。X射线晶体学的这种自动化和小型化在三维蛋白质结构分析中更加有效和高效,对工作流程产生了积极的影响。例如,LBNL的生物仪器团队与ALS、GNF的研究员和Syrrx合作,开发了第一代自动晶体识别和对准系统,打算在同步辐射光束线上工作。
在过去的几年里,药物发现和开发方面的研发活动不断增加,促进了市场的增长。这要归功于慢性、蛋白质缺乏的疾病和传染病的发病率上升。例如,从2010年到2019年,美国食品和药物管理局(FDA)平均批准了38种新药,比前十年的平均数多60%。蛋白质分析是识别潜在候选药物的一个关键阶段。另外,研发支出的后续增长也在推动全球市场的增长。根据Evaluate Pharma的报告,2012年全球医药研发支出为1360亿美元,到2019年将增至1860亿美元。
蛋白质结构分析设备技术发展的上升正在推动市场的增长。对蛋白质结构的高分辨率信息的需求不断增长,推动了市场的增长。无X射线电子激光器、D8 DISCOVER Plus X射线衍射(XRD)等先进技术的出现,由于提高了分析蛋白质三维结构的准确性和速度,对分析有帮助。例如,在2019年,安进公司(美国)和华盛顿大学的蛋白质设计研究所(IPD)合作,测试新技术,并产生可用于寻求新药物的蛋白质构建策略。
有了给定的市场数据,TechSci Research根据公司的具体需要提供定制服务。该报告有以下定制选项:
The global 3D protein structure analysis market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include a growing focus on automation and miniaturization in X-ray crystallography workflow, adoption of advanced technology, and rise in R&D activities that are augmenting the growth of the market. Protein structure is basically the three-dimensional arrangement of atoms in an amino acid. The three-dimensional structure of a protein at atomic resolution can be determined by crystallizing large proteins and then studying them by x-ray diffraction. Protein function is directly associated with the structure of that protein. The other factors supporting the market's growth are the rising demand for protein therapeutics, the rising prevalence of chronic, infectious, and protein-deficient diseases, the increase in the number of research laboratories, the high demand for personalized medicines, and increasing government grants. Also, the rising research and development (R&D) expenditure for drug discovery and development is facilitating the growth of the market.
X-Ray crystallography is a technique by which the 3D structure of a protein can be obtained by X-ray diffraction, which helps to know the functionality of the protein. Growing emphasis on automation and miniaturization of existing crystallography is augmenting the growth of the market. This automation and miniaturization of x-ray crystallography are positively influencing the workflow by being more effective and efficient in 3D protein structure analysis. For instance, the bio instrumentation team at LBNL collaborated with ALS, GNF's researcher, and Syrrx to develop a first-generation automated crystal recognition and alignment system intended to work at synchrotron beamlines.
Over the past few years, rising R&D activities in drug discovery and development is bolstering the growth of the market. This is attributed to the rising incidences of chronic, protein-deficient diseases and infectious diseases. For instance, the Food and Drug Administration (FDA) approved an average of 38 new drugs from 2010 to 2019, which is 60% more than the prior decade's average. Protein analysis is a crucial phase in identifying potential candidates. Also, the subsequent rise in R&D expenditure is propelling the growth of the market globally. As per the Evaluate Pharma report, pharmaceutical R&D expenditure globally was valued at USD 136 billion in 2012, which raised to USD 186 billion in 2019.
The rise in technological developments in equipment for protein structure analysis is fueling the growth of the market. The growing need for high-resolution information on protein structures is driving the growth of the market. The advent of advanced technologies like X-ray-free electron lasers, D8 DISCOVER Plus X-ray Diffraction (XRD), and others are helpful due to the enhanced accuracy and speed in analyzing the 3D structure of the protein. For instance, in 2019, Amgen (US) and the University of Washington's Institute for Protein Design (IPD) collaborated to test new technologies and generate protein-building tactics that can be applied to seek new drugs.
The global 3D protein structure analysis market is segmented into components, techniques, end users, and company. Based on components, the market is divided into instruments, consumables, and software. Based on technique, the market is divided into x-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, cryo-electron microscopy (Cryo-EM), and small angle x-ray scattering (SAXS). Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of chronic and infectious diseases in the country.
Bruker Corporation, JEOL Ltd., Spectris plc, Thermo Fisher Scientific Inc., Merck KGaA, Schrodinger, Inc., Cambridge Isotope Laboratories, Inc., Rigaku Corporation, Jena Bioscience GmbH, and Dassault Systemes SE are some of the leading companies operating in the market.
In this report, global 3D protein structure analysis market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global 3D Protein Structure Analysis Market
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: